How to buy Alterity Therapeutics stock - 19 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Alterity Therapeutics stock

Own Alterity Therapeutics stock in just a few minutes.

Alterity Therapeutics Limited is a biotechnology business based in the US. Alterity Therapeutics shares (ATHE) are listed on the NASDAQ and all prices are listed in US Dollars. Alterity Therapeutics employs 12 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Alterity Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Alterity Therapeutics. Find the stock by name or ticker symbol: ATHE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Alterity Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Alterity Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Alterity Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Alterity Therapeutics share price

Use our graph to track the performance of ATHE stocks over time.

Alterity Therapeutics shares at a glance

Information last updated 2021-04-14.
52-week rangeUSD$0.55 - USD$2.96
50-day moving average USD$1.52
200-day moving average USD$1.64
Wall St. target priceUSD$4.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.63

Buy Alterity Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Alterity Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alterity Therapeutics financials

Revenue TTM USD$28,153
Gross profit TTM USD$-352,922
Return on assets TTM -38.31%
Return on equity TTM -71.91%
Profit margin 0%
Book value $1.02
Market capitalisation USD$51.6 million

TTM: trailing 12 months

Shorting Alterity Therapeutics shares

There are currently 169,231 Alterity Therapeutics shares held short by investors – that's known as Alterity Therapeutics's "short interest". This figure is 18% up from 143,387 last month.

There are a few different ways that this level of interest in shorting Alterity Therapeutics shares can be evaluated.

Alterity Therapeutics's "short interest ratio" (SIR)

Alterity Therapeutics's "short interest ratio" (SIR) is the quantity of Alterity Therapeutics shares currently shorted divided by the average quantity of Alterity Therapeutics shares traded daily (recently around 313390.74074074). Alterity Therapeutics's SIR currently stands at 0.54. In other words for every 100,000 Alterity Therapeutics shares traded daily on the market, roughly 540 shares are currently held short.

However Alterity Therapeutics's short interest can also be evaluated against the total number of Alterity Therapeutics shares, or, against the total number of tradable Alterity Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alterity Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Alterity Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Alterity Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alterity Therapeutics.

Find out more about how you can short Alterity Therapeutics stock.

Alterity Therapeutics share dividends

We're not expecting Alterity Therapeutics to pay a dividend over the next 12 months.

Have Alterity Therapeutics's shares ever split?

Alterity Therapeutics's shares were split on a 1:6 basis on 23 March 2016. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alterity Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Alterity Therapeutics shares which in turn could have impacted Alterity Therapeutics's share price.

Alterity Therapeutics share price volatility

Over the last 12 months, Alterity Therapeutics's shares have ranged in value from as little as $0.55 up to $2.96. A popular way to gauge a stock's volatility is its "beta".

ATHE.US volatility(beta: 1.04)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alterity Therapeutics's is 1.0371. This would suggest that Alterity Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Alterity Therapeutics overview

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site